Telix Pharmaceuticals Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TLPPF research report →
About the company
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer.
- CEO
- Christian Behrenbruch
- IPO
- 2019
- Employees
- 1,120
- HQ
- North Melbourne, VIC, AU
Price Chart
- Market Cap
- $4.17B
- P/E
- -525.86
- P/S
- 4.67
- P/B
- 9.18
- EV/EBITDA
- 167.32
- Div Yield
- 0.00%
- Gross Margin
- 50.76%
- Op Margin
- 2.11%
- Net Margin
- -0.89%
- ROE
- -1.72%
- ROIC
- 1.77%
- Revenue
- $1.25B · 59.10%
- Net Income
- $-11,045,359 · -122.13%
- EPS
- $-0.03 · -121.80%
- Op Income
- $27.54M
- FCF YoY
- -1051.28%
- 52W High
- $16.76
- 52W Low
- $5.91
- 50D MA
- $10.07
- 200D MA
- $9.02
- Beta
- 0.63
- Avg Volume
- 3.77K
Get TickerSpark's AI analysis on TLPPF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our TLPPF coverage
Recent articles, reports, and earnings notes.
No research on TLPPF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TLPPF report →Similar companies
Peers in the same neighborhood.